The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review
El uso de isotretinoína aumenta el riesgo de enfermedad inflamatoria intestinal. Una revisión narrativa
Manuel Enrique Duarte-Arias, Juan Esteban Ospina-Gómez, María Paula Saavedra-Díaz
Abstract
Introduction: Acne vulgaris represents a prevalent dermatological condition capable of exerting a profound impact on an individual's quality of life. Isotretinoin, despite its well-established status as a highly effective remedy for severe acne, concerns surrounding the potential linkage with inflammatory bowel disease (IBD) have led to inquiries about its association.
Objective: The primary objective of this review is to critically assess the existing body of evidence pertaining to the efficacy and safety of isotretinoin, with a particular emphasis on its association with IBD.
Methods: A literature review was undertaken to examine the utilization of isotretinoin in the management of acne and to evaluate the subsequent risk of inflammatory bowel disease, aiming to determine the relevance of considering this factor when utilizing this treatment.
Conclusions: Isotretinoin is widely recognized as the most effective therapeutic approach to treat acne. This compound competently addresses all underlying factors contributing to acne pathogenesis. Over time, extensive deliberation has arisen concerning concerns related to its potential correlation with the onset of IBD. The currently available evidence conveys a paucity of substantial scientific support for a causal relationship between the use of isotretinoin and the development of IBD.
Keywords
Resumen
Introducción: El acné vulgaris representa una afección dermatológica prevalente capaz de ejercer un profundo impacto en la calidad de vida de un individuo. La isotretinoina, a pesar de su estatus bien establecido como un fármaco altamente efectivo para el acné severo, las preocupaciones en torno a la posible asociación con la enfermedad inflamatoria intestinal (EII) han llevado a investigaciones sobre su seguridad.
Objetivo: El objetivo principal de esta revisión es evaluar de manera crítica el cuerpo existente de evidencia relacionada con la eficacia y seguridad de la isotretinoína, con un énfasis particular en su asociación con la EII.
Métodos: Se realizó una revisión de la literatura para examinar la utilización de la isotretinoina en el tratamiento del acné y evaluar el riesgo subsiguiente de enfermedad inflamatoria intestinal, con el objetivo de determinar la relevancia de considerar este factor al utilizar este tratamiento.
Conclusiones: La isotretinoína es ampliamente reconocida como el enfoque terapéutico más efectivo para tratar el acné. Este compuesto aborda de manera competente todos los factores subyacentes que contribuyen a la patogénesis del acné. Con el tiempo, ha surgido una extensa deliberación con respecto a preocupaciones relacionadas con su posible correlación con el inicio de la EII. La evidencia científica actualmente disponible muestra un vacío significativo, que respalde un vínculo causal entre el uso de la isotretinoina y la aparición de la EII.
Palabras clave
References
1.Kaminsky A, Florez-White M, Arias MI, Bagatin E. Classification of acne: An Ibero-Latin American Consensus, 2014. Med Cutan Iber Lat Am. 2015;43(1):18-23.
2.Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008;9(5):279-84. doi: 10.2165/00128071-200809050-00001.
3.Ramrakha S, Fergusson DM, Horwood LJ, Dalgard F, Ambler A, Kokaua J, et al. Cumulative mental health consequences of acne: 23-year follow-up in a general population birth cohort study. Br J Dermatol. 2016;175(5):1079-81. doi: 10.1111/bjd.13786.
4.Sutaria AH, Masood S, Saleh HM, Schlessinger J. Acne Vulgaris. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
5.Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.
6.Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85(2):119-26. doi: 10.1111/j.1365-2133.1971.tb07195.x.
7.Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol. 2009;129(9):2136-41. doi: 10.1038/jid.2009.47.
8.Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13-25. doi: 10.2147/AHMT.S55832.
9.Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56-9. doi: 10.1016/j.jaad.2007.06.045.
10.Sharma S, Khaitan BK, Kumarasinghe SP. Cutaneous Signs in Dermatological Diseases; An Overview. Indian J Dermatol. 2021;66(5):530-9. doi: 10.4103/ijd.ijd_141_21.
11.Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-34. doi: 10.1038/jid.2013.446.
12.Del Rosso JQ, Kircik L. The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management. J Dermatolog Treat. 2024;35(1):2296855. doi: 10.1080/09546634.2023.2296855.
13.Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology. 2003;206(1):24-8. doi: 10.1159/000067819.
14.Evans DM, Kirk KM, Nyholt DR, Novac C, Martin NG. Teenage acne is influenced by genetic factors. Br J Dermatol. 2005;152(3):579-81. doi: 10.1111/j.1365-2133.2005.06387.x.
15.Habeshian KA, Cohen BA. Current Issues in the Treatment of Acne Vulgaris. Pediatrics. 2020;145(Suppl 2):S225-S230. doi: 10.1542/peds.2019-2056L.
16.Nast A, Rosumeck S, Erdmann R, Alsharif U, Dressler C, Werner RN. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016. J Eur Acad Dermatol Venereol. 2016;30(8):e1-e28. doi: 10.1111/jdv.13783.
17.Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162-9. doi: 10.4161/derm.1.3.9364.
18.Dessinioti C, Zouboulis CC, Bettoli V, Rigopoulos D. Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin. J Eur Acad Dermatol Venereol. 2020;34(10):2229-40. doi: 10.1111/jdv.16430.
19.Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76-85. doi: 10.1111/bjd.15668.
20.Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol. 2006;20(7):773-6. doi: 10.1111/j.1468-3083.2006.01671.x.
21.Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti Cet al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480-90. doi: 10.1111/jdv.13675.
22.Leyden JJ, Del Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. J Clin Aesthet Dermatol. 2014;7(2 Suppl):S3-S21.
23.Nast A, Bayerl C, Borelli C, Degitz K, Dirschka T, Erdmann R, et al. [S2k-guideline for therapy of acne]. J Dtsch Dermatol Ges. 2010;8 Suppl 2:s1-59. doi: 10.1111/j.1610-0387.2010.07466.x.
24.Coates P, Adams CA, Cunliffe WJ, McGinley KT, Eady EA, Leyden JJ, et al. Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology. 1997;195 Suppl 1:4-9; discussion 38-40. doi: 10.1159/000246012.
25.Villani A, Nastro F, Di Vico F, Fabbrocini G, Annunziata MC, Genco L. Oral isotretinoin for acne: a complete overview. Expert Opin Drug Saf. 2022;21(8):1027-37. doi: 10.1080/14740338.2022.2102605.
26.Kaminsky A. Less common methods to treat acne. Dermatology. 2003;206(1):68-73. doi: 10.1159/000067824.
27.Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33. doi: 10.1016/j.jaad.2015.12.037.
28.Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2016;188(2):118-26. doi: 10.1503/cmaj.140665.
29.Nast A, Rosumeck S, Erdmann R, Alsharif U, Dressler C, Werner RN. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016. J Eur Acad Dermatol Venereol. 2016;30(8):e1-e28. doi: 10.1111/jdv.13783.
30.Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):210-6. doi: 10.1097/MEG.0000000000000496.
31.Costa CS, Bagatin E, Martimbianco ALC, da Silva EM, Lúcio MM, Magin P, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018;11(11):CD009435. doi: 10.1002/14651858.CD009435.pub2.
32.Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010;105(9):1986-93. doi: 10.1038/ajg.2010.124.
33.Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol. 2013;133(4):907-12. doi: 10.1038/jid.2012.387.
34.Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216-20. doi: 10.1001/jamadermatol.2013.1344.
35.Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014;150(12):1322-6. doi: 10.1001/jamadermatol.2014.1540.
36.Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol. 2009;104(11):2774-8. doi: 10.1038/ajg.2009.417.
37.Racine A, Cuerq A, Bijon A, Ricordeau P, Weill A, Allemand H, et al. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. Am J Gastroenterol. 2014;109(4):563-9. doi: 10.1038/ajg.2014.8.
38.Yu CL, Chou PY, Liang CS, Chiang LH, Wang TY, Tu YK, et al. Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis. Am J Clin Dermatol. 2023;24(5):721-30. doi: 10.1007/s40257-023-00765-9.
39.Coughlin SS. Clarifying the Purported Association between Isotretinoin and Inflammatory Bowel Disease. J Environ Health Sci. 2015;1(2):10.15436/2378-6841.15.007. doi: 10.15436/2378-6841.15.007.
40.Miqdad MA, Alatta L, Abdelsamad A, Fouda S, Cherukuri ASS, Eltanany M, et al. Isotretinoin-Induced Inflammatory Bowel Disease: Is There a Real Association? Cureus. 2022;14(10):e29825. doi: 10.7759/cureus.29825.
41.Barbieri JS. Isotretinoin and risk of inflammatory bowel disease: More data to support lack of meaningful risk. J Am Acad Dermatol. 2021;84(1):228-9. doi: 10.1016/j.jaad.2020.07.041.
Submitted date:
04/10/2024
Reviewed date:
07/04/2024
Accepted date:
08/23/2024
Publication date:
08/28/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email